Streetwise Reports' Article Archives — March 2022 back to current month (21)
Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer.
Biotech Firm's Shares Double on $6B Deal (03/29/2022)
Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets.
STAAR Surgical Co. shares traded higher after the company reported that the U.S. FDA approved its EVO Visian® Implantable Collamer® Lenses to correct myopia (nearsightedness) and myopia with astigmatism.
Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma.
Biotech Co. Gets $2M Grant for Parkinson's Treatment (03/22/2022)
Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease.
Co. Awaits FDA Approval of Drug, Prepares for Launch (03/21/2022)
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report.
Drug Co. Gets PDUFA Date for TKI (03/20/2022)
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report.
Produce Co. to Acquire Grower of Greens (03/19/2022)
The transaction will increase the acquirer's returns and lower its operating risk, noted a ROTH Capital Partners report.
Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder.
Catalyst Could Push Pharma to Break Out (03/18/2022)
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says.
This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics.
Biopharma Co. Enjoys Gains From Kidney Cancer Drug (03/14/2022)
Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC).
License Revenues Kick in for Biopharma Co. (03/12/2022)
Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner.
Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings (03/10/2022)
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year.
Biotech Firm Should Increase Sales by 20% This Year (03/10/2022)
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report.
This medical device company is improving its laser ablation system and working toward U.S. approval for its use in a second application, noted a Ladenburg Thalmann report.
Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma.
Organogenesis Holdings Inc. shares traded 23% higher after the company reported FY/21 financial results that included a 46% YoY increase in revenue from its Advanced Wound Care products sales.
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report.
The 2022 outlook for a cancer detection and therapy solutions company is positive given its focus on dermatology and implementing new commercial strategies, noted an Oppenheimer report.
Primary Care Operator to Open 40 New Centers in 2022 (03/01/2022)
Shares of a Medicare-focused and AARP endorsed primary care facility operator traded 27% higher after the company reported FY/21 financial results that included a 64% YoY increase in capitated revenue.
|"Data presented by peers at the CTAD conference are relevant to PMN."|